Market

Huberman Lab Drops 3-Hour Peptides Masterclass With Dr. Abud Bakri

Huberman Lab aired a three-hour peptide deep dive with Dr. Abud Bakri on BPC-157, GHK-Cu, epitalon, GLP-1s, and the evidence gap driving todays peptide boom.

Last reviewed June 1, 2026

Andrew Huberman released a nearly three-hour Peptides Masterclass on June 1, 2026, featuring Dr. Abud Bakri — a board-certified internal medicine physician who runs a peptide-focused clinical practice. The episode quickly became one of the most discussed resources in the peptide space, offering millions of listeners a rare, physician-grounded tour through the science, sourcing, safety, and clinical reality of peptides.

Source: Huberman Lab

What the Episode Covers

Dr. Bakri walks through the full peptide landscape in an accessible but technically detailed format. The episode includes discussions of:

BPC-157 — its gastric origin story, the gap between animal and human data, and the neurological effects some users report
GHK-Cu — its role in wound healing, anti-inflammatory pathways, and the emerging research on copper peptide complexes
Epitalon (Epithalon) — the synthetic tetrapeptide based on epithalamine, its proposed effects on telomere length and pineal gland function
GLP-1 receptor agonists — semaglutide, tirzepatide, and retatrutide, including the compounding pharmacy supply chain and regulatory landscape
Melanotan — the tanning peptide’s risk profile and why it has attracted FDA scrutiny
Growth hormone secretagogues — ipamorelin, tesamorelin, and the distinction between peptide signaling and exogenous hormone replacement

The Evidence Gap: A Central Theme

One of the episode’s most significant contributions is its honest treatment of the evidence gap. Dr. Bakri acknowledges that the vast majority of mechanistic data for popular research peptides comes from animal models and in vitro studies, with very few well-controlled human trials. He notes, for example, that the typical 200–250 microgram dose of BPC-157 used by consumers is not derived from any human dose-finding study — it is based on peptide vendor websites.

This transparency matters because the peptide market has grown far faster than the evidence base. The same tension between enthusiastic adoption and limited clinical data was highlighted in last month’s Lancet warning on the peptide craze and the STAT News investigation into the origins of BPC-157.

The Compounding Pharmacy Economics

Dr. Bakri also addresses the financial dynamics that increasingly define the peptide space. He describes what he calls the “dirty secret” of compounding: physicians often acquire peptides from compounding pharmacies at cost and charge patients a markup without disclosing the margin. This business model, he argues, creates an inherent conflict of interest — the physician has a financial incentive to prescribe peptides regardless of whether the evidence supports their use for a given patient.

This discussion aligns with the broader regulatory conversation around compounding transparency, including the FDA’s April 2026 proposal to exclude GLP-1s from the 503B bulks list over manufacturing quality concerns.

Why the Huberman Episode Matters

The Huberman Lab podcast reaches millions of subscribers across YouTube, Spotify, and Apple Podcasts. A dedicated three-hour peptide episode signals that peptides have moved from a niche biohacker interest into the mainstream health conversation. When a major science communicator like Andrew Huberman dedicates this much airtime to peptide science — complete with sourced references, peer-reviewed studies, and physician insight — it accelerates public understanding and, inevitably, public demand.

For policymakers and regulators preparing for the July 23–24 PCAC meeting, this level of mainstream attention is a double-edged sword: it increases pressure to act, but also raises the stakes for getting the regulatory framework right.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.